The FDA has accepted applications for three new indications for bimekizumab-bkzx, a humanized interleukin (IL) 17A and IL-17F antagonist: psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Search results for: hospital
A Fellow’s Experience at Advocacy 101
Rheumatology fellow Audrey Liu, MD, describes the excitement and empowerment of seeing first-hand the real-world impact of advocating for policies that support providers and patients.
Rheum After 5: Dr. Usman Malik on the Art of Writing
Novice writers often wait months, sometimes even years, before their first piece is published. However, Usman T. Malik, MBBS, shares a different experience. His letter to the editor of Bachon ka Pakistan, a Pakistani children’s publication, was published shortly after being submitted. He was just 7 years old. Dr. Malik is now an assistant professor…
Ethics Forum: The Current Landscape of Artificial Intelligence in Medicine
A handful of articles on artificial intelligence (AI) have graced the pages of this publication in the past six years, including one by Bharat Kumar, MD, in November 2022. Dr. Kumar highlighted the exciting potential of AI in rheumatology, including machine learning (ML) algorithms for the prediction of response to methotrexate and a predictive model…
FTC Bans Noncompete Agreements: What Rheumatologists Need to Know
The ACR applauds the FTC’s recent ban on most noncompete agreements. The ruling is a step in the right direction toward a more competitive market for healthcare workers and their services.
Case Report: Persistent Pruritic Plaques in Adult-Onset Still’s Disease
Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder characterized by persistent fever at regular intervals, arthralgias or arthritis, rash, sore throat and neutrophilic leukocytosis.1,2 Significant elevation in ferritin levels is characteristic and tends to correlate with disease activity. Additional clinical features may include myalgias, lymphadenopathy, hepatosplenomegaly, serositis, myocarditis, abnormal liver function tests and development…
3 AC&R Study Summaries: Frailty & Prefrailty in RA, Premature Mortality in Gout & Using Recruitment & Multidisciplinary Care Incentives to Improve Access
Frailty & Prefrailty in Patients with RA TNF-α inhibitors associated with higher infection risk By Namrata Singh, MD, MSCI, Katherine D. Wysham, MD, James S. Andrews, MD, & Una E. Makris, MD Why was this study done? Frailty and prefrailty are more common and occur at a younger age in patients with rheumatoid arthritis (RA)…
Rheumatology’s Systems-Based Thinking Plays Well on Capitol Hill
One of the great joys of rheumatology is that it prioritizes systems-based thinking. Whether integrating data from radiographic imaging or piecing together a puzzling case of autoimmunity, rheumatologists are tasked with understanding how systems fundamentally work. In fact, this emphasis on systems-based thinking is often what draws and keeps the best and smartest physicians within…
Biosimilars to Denosumab Approved with an Interchangeable Designation
The FDA has approved the first interchangeable biosimilars for denosumab.
Clinically Significant Pain Relief with a Non-Opioid Drug
In a phase 3 trial, treatment with VX-548 led to statistically and clinically significant improvements in pain compared with placebo.
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 330
- Next Page »